Carlyle-backed SeQuent Scientific to merge Viyash Lifesciences in an INR80bn deal.

Carlyle-backed SeQuent Scientific, an animal health company, agreed to merge Viyash Lifesciences, an integrated global pharmaceutical company, in an INR80bn deal. "We are excited to merge forces with SeQuent and create an elevated entity that is uniquely positioned. This merger brings together two complementary businesses that share a commitment to innovation, operational excellence, and delivering world-class solutions for our customers. With our combined resources, R&D capabilities, manufacturing capacities, and streamlined supply chain, we are well-positioned to accelerate growth and offer a wider range of high-quality products to our customers," Haribabu Bodepudi, Viyash Chairman and CEO.